Tarsus Pharmaceuticals: Marketing Spend Bears Fruit, Pipeline Progresses [Seeking Alpha]
Tarsus Pharmaceuticals, Inc. (TARS)
Company Research
Source: Seeking Alpha
The company has appointed star biotech executive David Pyott, former CEO and Chairman of Allergan Inc, to the Board. TARS has H1'27 clinical catalysts from trials of lotilaner in Lyme-disease prevention/tick-killing and ocular rosacea. TARS believes TP-03/Xdemvy is on track for 2027 regulatory approval in Europe in Demodex blepharitis. t_kimura/iStock via Getty Images Tarsus Pharmaceuticals ( TARS ) continues to aggressively market Xdemvy (loitilaner) for Demodex blepharitis (DB), with that push is showing signs of being worthwhile. When I last wrote about TARS in September 2025, I considered whether or not the big This article was written by Analyst's Disclosure: I/we have a beneficial long position in the shares of TARS either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose s
Show less
Read more
Impact Snapshot
Event Time:
TARS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TARS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TARS alerts
High impacting Tarsus Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
TARS
News
- Tarsus Pharmaceuticals (TARS) was upgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=TARS&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from "hMarketBeat
- How TP-05's Phase 2 Lyme Prophylaxis Trial Progress Could Impact Tarsus Pharmaceuticals (TARS) Investors [Yahoo! Finance]Yahoo! Finance
- Tarsus Doses First Participant in Calliope, A Phase 2 Clinical Trial of TP-05 (lotilaner), a Novel Investigational Oral Tablet for the Potential Prevention of Lyme DiseaseGlobeNewswire
- Tarsus Pharma Stock Up 20% as Insider Sells $839K in RSU-Linked Trade [Yahoo! Finance]Yahoo! Finance
- TP-03 (lotilaner ophthalmic solution) 0.25% Now Approved in China for the Treatment of Demodex Blepharitis, Triggering a $15M Milestone Payment to Tarsus [Yahoo! Finance]Yahoo! Finance
TARS
Earnings
- 2/23/26 - Miss
TARS
Sec Filings
- 3/27/26 - Form SCHEDULE
- 3/24/26 - Form 4
- 3/20/26 - Form 144
- TARS's page on the SEC website